ArriVent BioPharma Inc. Common Stock (AVBP)
Company Info
Highlights
$896.35M
-$2.61
-$70.60M
$14.35 - $36.37
$38.60
18.00%
31.00
Share Price Chart
Loading data...
Compare to other instruments
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
Performance Chart
The chart shows the growth of an initial investment of $10,000 in ArriVent BioPharma Inc. Common Stock, comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.
Returns By Period
ArriVent BioPharma Inc. Common Stock had a return of -0.15% year-to-date (YTD) and 18.38% in the last 12 months.
AVBP
-0.15%
8.97%
10.88%
18.38%
N/A
N/A
^GSPC (Benchmark)
3.96%
1.97%
9.03%
22.16%
12.60%
11.26%
Monthly Returns
The table below presents the monthly returns of AVBP, with color gradation from worst to best to easily spot seasonal factors. Returns are adjusted for dividends.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025 | 7.13% | -0.15% | |||||||||||
| 2024 | 7.75% | -0.05% | -17.08% | -7.50% | 17.49% | -4.43% | 18.06% | 22.05% | -12.08% | 24.85% | 2.11% | -11.08% | 33.20% |
Risk-Adjusted Performance
Risk-Adjusted Performance Rank
The current rank of AVBP is 59, indicating average performance compared to other stocks on our website. Here’s a breakdown of how it compares using common performance measures.
Risk-Adjusted Performance Indicators
The charts below present risk-adjusted performance metrics for ArriVent BioPharma Inc. Common Stock (AVBP) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Worst Drawdowns
The table below displays the maximum drawdowns of the ArriVent BioPharma Inc. Common Stock. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the ArriVent BioPharma Inc. Common Stock was 32.75%, occurring on Apr 24, 2024. Recovery took 73 trading sessions.
The current ArriVent BioPharma Inc. Common Stock drawdown is 25.34%.
Depth | Start | To Bottom | Bottom | To Recover | End | Total |
|---|---|---|---|---|---|---|
| -32.75% | Mar 5, 2024 | 36 | Apr 24, 2024 | 73 | Aug 8, 2024 | 109 |
| -31.49% | Nov 8, 2024 | 47 | Jan 17, 2025 | — | — | — |
| -19.17% | Sep 9, 2024 | 11 | Sep 23, 2024 | 14 | Oct 11, 2024 | 25 |
| -15.71% | Feb 20, 2024 | 5 | Feb 26, 2024 | 5 | Mar 4, 2024 | 10 |
| -8.8% | Oct 29, 2024 | 3 | Oct 31, 2024 | 4 | Nov 6, 2024 | 7 |
Volatility
Volatility Chart
The current ArriVent BioPharma Inc. Common Stock volatility is 13.49%, representing the average percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.
Financials
Financial Performance
Historical P/E Ratio Chart
The chart below displays the historical trend of the price-to-earnings (P/E) ratio for ArriVent BioPharma Inc. Common Stock.
Loading data...
Income Statement
| TTM | |
|---|---|
Revenue | |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |